Chronic kidney disease ⭐

ckd · society: KDIGO · high-yield

← back to Nephrology

Summary

KDIGO 2024 updates the 2012 CKD guideline with major changes including endorsement of eGFRcr-cys (creatinine + cystatin C) for accurate staging, race-free GFR estimation, validated risk equations (KFRE) to drive referral and modality decisions, and strong recommendations for SGLT2 inhibitors across diabetic and non-diabetic CKD. New emphasis on a holistic, multi-drug treatment paradigm (RASi + SGLT2i + statin + nonsteroidal MRA in T2D), risk-based rather than eGFR-only management, and structured drug stewardship/imaging guidance. Scope covers adults and children with non-dialysis, non-transplant CKD.

Current guideline: KDIGO 2024 CKD Guideline · download Anki sub-deck

Versions